Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (9)
Ignacio Catalan-Serra & Øystein Brenna. (2018) Immunotherapy in inflammatory bowel disease: Novel and emerging treatments. Human Vaccines & Immunotherapeutics 14:11, pages 2597-2611.
Read now
Read now
Annalisa Tonini, Bruno Gualtieri, Salvatore Panduri, Marco Romanelli & Andrea Chiricozzi. (2018) A new class of biologic agents facing the therapeutic paradigm in psoriasis: anti-IL-23 agents.. Expert Opinion on Biological Therapy 18:2, pages 135-148.
Read now
Read now
Bram Verstockt, Barbara Deleenheer, Gert Van Assche, Séverine Vermeire & Marc Ferrante. (2017) A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert Opinion on Drug Safety 16:7, pages 809-821.
Read now
Read now
Andrea Chiricozzi, Dante Caposiena, Virginia Garofalo, Maria Vittoria Cannizzaro, Sergio Chimenti & Rosita Saraceno. (2016) A new therapeutic for the treatment of moderate-to-severe plaque psoriasis: apremilast. Expert Review of Clinical Immunology 12:3, pages 237-249.
Read now
Read now
Alejandro Souto & Juan J Gómez-Reino. (2015) Apremilast for the treatment of psoriatic arthritis. Expert Review of Clinical Immunology 11:12, pages 1281-1290.
Read now
Read now
Nicole C. Rouse, Michael E. Farhangian, Brooke Wehausen & Steven R. Feldman. (2015) The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Review of Pharmacoeconomics & Outcomes Research 15:6, pages 877-884.
Read now
Read now
Maria Sole Chimenti, Talia Gramiccia, Rosita Saraceno, Luca Bianchi, Virginia Garofalo, Oreste Buonomo, Roberto Perricone, Sergio Chimenti & Andrea Chiricozzi. (2015) Apremilast for the treatment of psoriasis. Expert Opinion on Pharmacotherapy 16:13, pages 2083-2094.
Read now
Read now
David John Chandler & Anthony Bewley. (2014) Ustekinumab for the treatment of psoriatic arthritis. Expert Review of Clinical Pharmacology 7:2, pages 111-121.
Read now
Read now
Bobbak Mansouri, Mahir Patel & Alan Menter. (2013) Biological therapies for psoriasis. Expert Opinion on Biological Therapy 13:12, pages 1715-1730.
Read now
Read now
Articles from other publishers (28)
Jinling XuHuaxing MaLingfeng ShiHui ZhouYangyang ChengJiayue TongBiying MengXiaoli Xu, Kaiyue HeSheng DingZhang JiajiaLing YueXiang Guangda. (2023) Inflammatory Cell–Derived MYDGF Attenuates Endothelial LDL Transcytosis to Protect Against Atherogenesis. Arteriosclerosis, Thrombosis, and Vascular Biology.
Crossref
Crossref
Brittany Weber & Katherine P. Liao. (2023) Evidence for Biologic Drug Modifying Anti-Rheumatoid Drugs and Association with Cardiovascular Disease Risk Mitigation in Inflammatory Arthritis. Rheumatic Disease Clinics of North America 49:1, pages 165-178.
Crossref
Crossref
Haamid Bashir, Mohammad Hayat Bhat, Shafat Ali, Naieem Ahmad Pir, Faizan- i- Asrar Nazki & Sabhiya Majid. 2022. Clinical Applications of Immunogenetics. Clinical Applications of Immunogenetics
377
389
.
Mario Fernández-Ruiz. 2022. Infectious Complications in Biologic and Targeted Therapies. Infectious Complications in Biologic and Targeted Therapies
199
217
.
Brittany Weber, Joseph F. Merola, M. Elaine Husni, Marcelo Di Carli, Jeffrey S. Berger & Michael S. Garshick. (2021) Psoriasis and Cardiovascular Disease: Novel Mechanisms and Evolving Therapeutics. Current Atherosclerosis Reports 23:11.
Crossref
Crossref
Athina Trakaki, Peter Wolf, Wolfgang Weger, Thomas O. Eichmann, Hubert Scharnagl, Julia T. Stadler, Wolfgang Salmhofer, Eva Knuplez, Michael Holzer & Gunther Marsche. (2021) Biological anti-psoriatic therapy profoundly affects high-density lipoprotein function. Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids 1866:7, pages 158943.
Crossref
Crossref
Ahmad Ismail Khaled Abdo & Gee Jun Tye. (2020) Interleukin 23 and autoimmune diseases: current and possible future therapies. Inflammation Research 69:5, pages 463-480.
Crossref
Crossref
Craig A. Elmets, Craig L. Leonardi, Dawn M.R. Davis, Joel M. Gelfand, Jason Lichten, Nehal N. Mehta, April W. Armstrong, Cody Connor, Kelly M. Cordoro, Boni E. Elewski, Kenneth B. Gordon, Alice B. Gottlieb, Daniel H. Kaplan, Arthur Kavanaugh, Dario Kivelevitch, Matthew Kiselica, Neil J. Korman, Daniela Kroshinsky, Mark Lebwohl, Henry W. Lim, Amy S. Paller, Sylvia L. Parra, Arun L. Pathy, Elizabeth Farley Prater, Reena Rupani, Michael Siegel, Benjamin Stoff, Bruce E. Strober, Emily B. Wong, Jashin J. Wu, Vidhya Hariharan & Alan Menter. (2019) Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with awareness and attention to comorbidities. Journal of the American Academy of Dermatology 80:4, pages 1073-1113.
Crossref
Crossref
Youssef A Elnabawi, Amit K Dey, Aditya Goyal, Jacob W Groenendyk, Jonathan H Chung, Agastya D Belur, Justin Rodante, Charlotte L Harrington, Heather L Teague, Yvonne Baumer, Andrew Keel, Martin P Playford, Veit Sandfort, Marcus Y Chen, Benjamin Lockshin, Joel M Gelfand, David A Bluemke & Nehal N Mehta. (2019) Coronary artery plaque characteristics and treatment with biologic therapy in severe psoriasis: results from a prospective observational study. Cardiovascular Research 115:4, pages 721-728.
Crossref
Crossref
Alexander R. Moschen, Herbert Tilg & Tim Raine. (2018) IL-12, IL-23 and IL-17 in IBD: immunobiology and therapeutic targeting. Nature Reviews Gastroenterology & Hepatology 16:3, pages 185-196.
Crossref
Crossref
Frank R. Brennan, Emma Smith & Sherri Dudal. 2019. Nijkamp and Parnham's Principles of Immunopharmacology. Nijkamp and Parnham's Principles of Immunopharmacology
369
406
.
Hang Hock Shim, Pak Wo Chan, Sai Wei Chuah, Brian J Schwender, San Choon Kong & Khoon Lin Ling. (2018) A review of vedolizumab and ustekinumab for the treatment of inflammatory bowel diseases. JGH Open 2:5, pages 223-234.
Crossref
Crossref
Janaiya S. Samuels, Lauren Holland, María López, Keya Meyers, William G. Cumbie, Anna McClain, Aleksandra Ignatowicz, Daryllynn Nelson & Rangaiah Shashidharamurthy. (2018) Prostaglandin E2 and IL-23 interconnects STAT3 and RoRγ pathways to initiate Th17 CD4+ T-cell development during rheumatoid arthritis. Inflammation Research 67:7, pages 589-596.
Crossref
Crossref
Anna Moltó & Elena Nikiphorou. (2018) Comorbidities in Spondyloarthritis. Frontiers in Medicine 5.
Crossref
Crossref
Chau Yee Ng, I-Shiang Tzeng, Su-Hsun Liu, Ya-Ching Chang & Yu-Huei Huang. (2018)
Retracted
: Metabolic parameters in psoriatic patients treated with interleukin-12/23 blockade (ustekinumab)
. The Journal of Dermatology 45:3, pages 309-313.
Crossref
Crossref
Pieter Hindryckx, Niels Vande Casteele, Gregor Novak, Reena Khanna, Geert D’Haens, William J Sandborn, Silvio Danese, Vipul Jairath & Brian G Feagan. (2018) The Expanding Therapeutic Armamentarium for Inflammatory Bowel Disease: How to Choose the Right Drug[s] for Our Patients?. Journal of Crohn's and Colitis 12:1, pages 105-119.
Crossref
Crossref
Andrew Blauvelt. 2018. Biologic and Systemic Agents in Dermatology. Biologic and Systemic Agents in Dermatology
123
131
.
G. Girolomoni, R. Strohal, L. Puig, H. Bachelez, J. Barker, W.H. Boehncke & J.C. Prinz. (2017)
The role of IL-23 and the IL-23/T
H
17 immune axis in the pathogenesis and treatment of psoriasis
. Journal of the European Academy of Dermatology and Venereology 31:10, pages 1616-1626.
Crossref
Crossref
Megan Yu, Sheng-Feng Tsai & Yu-Min Kuo. (2017) The Therapeutic Potential of Anti-Inflammatory Exerkines in the Treatment of Atherosclerosis. International Journal of Molecular Sciences 18:6, pages 1260.
Crossref
Crossref
Lauren Guggina & Kenneth B. Gordon. 2017. Clinical and Basic Immunodermatology. Clinical and Basic Immunodermatology
757
765
.
Virendra N. Sehgal, Deepika Pandhi & Ananta Khurana. (2015) Biologics in dermatology: adverse effects. International Journal of Dermatology 54:12, pages 1442-1460.
Crossref
Crossref
K Köck, W J Pan, J M Gow, M J Horner, J P Gibbs, A Colbert, T J Goletz, K J Newhall, W A Rees, Y Sun, Y Zhang, J C O'Neill, A N Umble-Romero, S P Prokop, C D Krill, L Som, S A Buntich, M W Trimble, W H Tsuji & J E Towne. (2015) Preclinical development of AMG 139, a human antibody specifically targeting IL-23. British Journal of Pharmacology 172:1, pages 159-172.
Crossref
Crossref
Olubukola Babalola, Nikita Lakdawala & Bruce E. Strober. (2015) Combined biologic therapy for the treatment of psoriasis and psoriatic arthritis: A case report. JAAD Case Reports 1:1, pages 3-4.
Crossref
Crossref
JIA YIN YAO, YI LU, MIN ZHI, CHU JUN LI, PIN JIN HU & XIANG GAO. (2014) Inhibition of the interleukin-23/interleukin-17 pathway by anti-interleukin-23p19 monoclonal antibody attenuates 2,4,6-trinitrobenzene sulfonic acid-induced Crohn’s disease in rats. Molecular Medicine Reports 10:4, pages 2105-2110.
Crossref
Crossref
Frank R. Brennan. 2014. Handbook of Therapeutic Antibodies. Handbook of Therapeutic Antibodies
969
1078
.
John Koo, Ethan Levin, Argentina Leon, Jashin Wu & Alice GottliebAndrew Blauvelt. 2014. Moderate to Severe Psoriasis, Fourth Edition. Moderate to Severe Psoriasis, Fourth Edition
217
230
.
Thrasivoulos Tzellos, Athanassios Kyrgidis, Anastasia Trigoni & Christos C. Zouboulis. (2014) Point: Major adverse cardiovascular events and anti-IL 12/23 agents. Journal of the American Academy of Dermatology 70:2, pages 380-381.
Crossref
Crossref
Brian A. Baldo. 2014. A worldwide yearly survey of new data in adverse drug reactions. A worldwide yearly survey of new data in adverse drug reactions
561
590
.